Rehabilitation at Home Using Mobile Health In Older Adults After Hospitalization for Ischemic Heart Disease (RESILIENT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03978130 |
Recruitment Status :
Active, not recruiting
First Posted : June 6, 2019
Last Update Posted : March 6, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ischemic Heart Disease | Other: mHealth-CR | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 400 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Masking Description: | partial mask (outcomes assessor) |
Primary Purpose: | Treatment |
Official Title: | REhabilitation at Home uSIng mobiLe Health In oldEr Adults After hospitalizatioN for Ischemic hearT Disease |
Actual Study Start Date : | January 9, 2020 |
Actual Primary Completion Date : | January 10, 2024 |
Estimated Study Completion Date : | April 30, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: mHealth-CR |
Other: mHealth-CR
Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device. |
No Intervention: Usual Care |
- Change in 6-minute walking distance (6MWD) [ Time Frame: 3 month ]Change in 6MWD, reflective of functional capacity, is measured by the 6-minute walk test (6MWT). The 6-minute walk test (6MWT) is a submaximal exercise test in which the pace is self-selected by the participant. The 6MWT will be performed during baseline hospitalization and at the 3-month follow-up visit by a blinded research nurse.
- Goal Attainment measured using a 5-point goal attainment scale (GAS) [ Time Frame: 3 month ]Using the SMART goal framework, GAS describes the person's expected level of goal achievement over 3 months, ranging from no change (scored as -2) to much better than expected (scored as +2) out of a 5 point-scale. Scales are dynamically set according to a person's needs, while measurement of attainment is standardized. Overall score is calculated by incorporating the goal of outcomes scores into an aggregated t-score. Goal attainment, through goal setting, is an especially important outcome in older adults who may begin an intervention with a variety of deficits (therefore necessitating individualized therapy towards realistic goals).
- Participant reported health status - measured using the SF-12 [ Time Frame: 3 month ]Health status encompasses a person's functional status, symptoms, and wellbeing, and is increasingly recognized as an important patient-centered outcome. Both the SF-12 and SAQ-7 have been validated and are convenient for participants (<5 minutes to administer). For the SF-12, we will analyze change from baseline to 3 months using a threshold of 5 points in SF-12 physical component score (PCS) as a clinically meaningful change
- Participant reported health status - measured Seattle Angina Questionnaire 7 (SAQ-7) (disease-specific health status). [ Time Frame: 3 month ]Health status encompasses a person's functional status, symptoms, and wellbeing, and is increasingly recognized as an important patient-centered outcome. Both the SF-12 and SAQ-7 have been validated and are convenient for participants (<5 minutes to administer). For SAQ-7, we will analyze at a single time point (3 months) the number of participants who have residual angina (SAQ-7<100) vs. no angina (SAQ-7=100).
- Change in Basic Activities of Daily Living (BADLs) [ Time Frame: 3 month ]defined as any improvement or worsening in basic (BADLs) over 3 months. BADLs are basic self-care behaviors: feeding, toileting, bathing, dressing, and ambulating. I
- Change in Activities of Daily Living (ADLs) [ Time Frame: 3 months. ]defined as any improvement or worsening in instrumental (IADLs) activities of daily living over 3 months. ADLs are activities that allow a person to live independently (e.g. food preparation, medication management, transportation, shopping, managing finances, using the telephone, and housekeeping).
- Hospital readmissions evaluated at 3, 6 and 12 Months [ Time Frame: 1 Year ]Defined as number of participants who were readmitted into the hospital with an overnight stay (including observation) in any hospital within 3, 6, and 12 months of hospitalization. Data are obtainable via the electronic health record (EHR).
- Death [ Time Frame: 1 Year ]is defined by number of participants who died from any cause within 3, 6, and 12 months of enrollment. Data are obtainable via the electronic health record (EHR).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 65 Years to 110 Years (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥65
- Currently hospitalized for AMI, PCI, or CABG or Hospitalized for AMI, PCI or CABG within prior 2 weeks.
- Capable of self-consent.
- Understand and are able to perform study procedures (i.e. 6-minute walk test, use mHealth in English or Spanish).
Exclusion Criteria:
- Non-ambulatory.
- Moderate or severe cognitive impairment.
- Unable/unwilling to consent.
- PCI-related groin hematoma that precludes brisk walking.
- Incarcerated.
- Unable to use mHealth software in English or Spanish.
- Severe osteoarthritis, or joint replacement within last 3 months.
- Parkinson's disease or other progressive movement disorder.
- Regular use of walker for ambulation.
- Projected life expectancy <3 months.
- Clinical judgment concerning other safety or nonadherence issues.
- Participants admitted from long-term care facility.
- Currently listed for heart transplant.
- Left ventricular assist device recipient.
- Completion of ambulatory cardiac rehabilitation program within prior 3 months.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03978130
United States, Massachusetts | |
UMass Chan Medical School | |
Worcester, Massachusetts, United States, 01655 | |
United States, New York | |
NYU Langone Health | |
New York, New York, United States, 10016 |
Principal Investigator: | John Dodson, MD | New York Langone Health |
Responsible Party: | NYU Langone Health |
ClinicalTrials.gov Identifier: | NCT03978130 |
Other Study ID Numbers: |
18-02017 |
First Posted: | June 6, 2019 Key Record Dates |
Last Update Posted: | March 6, 2024 |
Last Verified: | March 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) |
Time Frame: | Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research. |
Access Criteria: | Requests should be directed to john.dodson@nyumc.org. To gain access, data requestors will need to sign a data access agreement. The investigator who proposed to use the data. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Heart Diseases Myocardial Ischemia Coronary Artery Disease Ischemia Pathologic Processes |
Cardiovascular Diseases Vascular Diseases Coronary Disease Arteriosclerosis Arterial Occlusive Diseases |